stoxline Quote Chart Rank Option Currency Glossary
Zymeworks Inc. (ZYME)
9.15  0.28 (3.16%)    12-01 16:00
Open: 8.81
High: 9.175
Volume: 287,729
Pre. Close: 8.87
Low: 8.72
Market Cap: 641(M)
Technical analysis
2023-12-01 4:23:46 PM
Short term     
Mid term     
Targets 6-month :  10.9 1-year :  12.74
Resists First :  9.34 Second :  10.9
Pivot price 8.2
Supports First :  7.59 Second :  6.51
MAs MA(5) :  8.81 MA(20) :  7.95
MA(100) :  7.27 MA(250) :  8.07
MACD MACD :  0.4 Signal :  0.3
%K %D K(14,3) :  88.2 D(3) :  90.6
RSI RSI(14): 77.4
52-week High :  10.8 Low :  5.76
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ZYME ] has closed below upper band by 7.1%. Bollinger Bands are 102.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.18 - 9.21 9.21 - 9.24
Low: 8.64 - 8.67 8.67 - 8.71
Close: 9.09 - 9.14 9.14 - 9.2
Company Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Headline News

Fri, 01 Dec 2023
Does Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as ... - Yahoo Finance

Thu, 30 Nov 2023
Zymeworks Announces Participation in Upcoming Investor Conference - Yahoo Finance

Wed, 15 Nov 2023
Wall Street Analysts Predict a 64.61% Upside in Zymeworks Inc ... - Nasdaq

Sun, 12 Nov 2023
Validea's Top Health Care Stocks Based On Benjamin Graham - 11 ... - Nasdaq

Wed, 08 Nov 2023
Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript - Yahoo Finance

Wed, 01 Nov 2023
Zymeworks Announces Participation in Upcoming Investor Conferences - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 70 (M)
Shares Float 42 (M)
Held by Insiders 4.8 (%)
Held by Institutions 96.4 (%)
Shares Short 2,420 (K)
Shares Short P.Month 4,680 (K)
Stock Financials
EPS 3.23
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.25
Profit Margin 44.4 %
Operating Margin -201.3 %
Return on Assets (ttm) 29.7 %
Return on Equity (ttm) 67.9 %
Qtrly Rev. Growth 527.4 %
Gross Profit (p.s.) 2.91
Sales Per Share 6.59
EBITDA (p.s.) 3.01
Qtrly Earnings Growth 0 %
Operating Cash Flow 195 (M)
Levered Free Cash Flow 111 (M)
Stock Valuations
PE Ratio 2.83
PEG Ratio -0.4
Price to Book value 1.46
Price to Sales 1.38
Price to Cash Flow 3.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android